Table 3 Adverse events
AE | All grade | 3/4 | 1 | 2 | 3 | 4 |
|---|---|---|---|---|---|---|
Anemia | 21(25.00%) | 4(4.76%) | 7(8.33%) | 10(11.90%) | 4(4.76%) | 0 |
Neutropenia | 63(75.00%) | 38(45.24%) | 7(8.33%) | 18(21.43%) | 21(25.00%) | 17(20.24%) |
Thrombocytopenia | 17(20.24%) | 7(8.33%) | 1(1.19%) | 9(10.71%) | 6(7.14%) | 1(1.19%) |
Neuropathy | 42(50.00%) | 6(7.14%) | 27(32.14%) | 9(10.71%) | 6(7.14%) | 0 |
Diarrhea | 2(2.38%) | 0 | 1(1.19%) | 1(1.19%) | 0 | 0 |
Anorexia | 3(3.57%) | 0 | 3(3.57%) | 0 | 0 | 0 |
Fatigue | 14(16.67%) | 0 | 9(10.71%) | 5(5.95%) | 0 | 0 |
Rash | 28(33.33%) | 2(2.38%) | 15(17.86%) | 11(13.09%) | 2(2.38%) | 0 |
Blurred vision | 8(9.53%) | 0 | 7(8.33%) | 1(1.19%) | 0 | 0 |
Dry eye | 1(1.19%) | 0 | 1(1.19%) | 0 | 0 | 0 |
Eye pain | 1(1.19%) | 0 | 1(1.19%) | 0 | 0 | 0 |
Alopecia | 34(40.48%) | 0 | 6(7.14%) | 28(33.33%) | 0 | 0 |
Nausea and vomiting | 21(25.00%) | 0 | 17(20.24%) | 4(4.76%) | 0 | 0 |
Nail change | 19(22.62%) | 0 | 15(17.86%) | 4(4.76%) | 0 | 0 |
Mucositis | 6(7.14%) | 0 | 2(2.38%) | 3(3.57%) | 1(1.19%) | 0 |
Edema | 20(23.80%) | 0 | 14(16.67%) | 6(7.14%) | 0 | 0 |
Liver enzyme escalation | 6(7.14%) | 0 | 3(3.57%) | 3(3.57%) | 0 | 0 |
Hematuria | 2(2.38%) | 0 | 2(2.38%) | 0 | 0 | 0 |
Skin hyperpigmentation | 8(9.53%) | 0 | 8(9.53%) | 0 | 0 | 0 |
Hyperhidrosis | 1(1.19%) | 1(1.19%) | 0 | 0 | 1(1.19%) | 0 |
Febrile neutropenia | 2(2.38%) | 2(2.38%) | 0 | 0 | 1(1.19%) | 1(1.19%) |
Myalgia | 20(23.81%) | 0 | 17(20.24%) | 2(2.38%) | 1(1.19%) | 0 |
Hypersensitivity | 1(1.19%) | 1(1.19%) | 0 | 0 | 1(1.19%) | 0 |
Epistaxis | 2(2.38%) | 0 | 2(2.38%) | 0 | 0 | 0 |
Abdominal distension | 3(3.57%) | 0 | 2(2.38%) | 1(1.19%) | 0 | 0 |
Pneumonitis | 1(1.19%) | 0 | 0 | 1(1.19%) | 0 | 0 |